Oncovin

Oncovin treats certain types of cancer. Can cause tingling sensation and numbness in the fingers and toes.

Oncovin Overview

Updated: 

Oncovin is a prescription medication used to treat acute leukemia. Oncovin is also used in combination with other medicines to treat Hodgkin’s disease, non-Hodgkin’s lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms’ tumor.

Oncovin belongs to a group of drugs called vinca alkaloids. It works by slowing or stopping the growth of cancer cells in your body.

This medication comes in an injectable form to be given directly into a vein (IV) by a healthcare provider. It is usually given once a week.

Common side effects of Oncovin include hair loss, nausea, constipation, plus weakness, numbness, and pain, usually in the hands and feet (peripheral neuropathy).

This brand is no longer available, but the generic vincristine sulfate is available. 

Patient Ratings for Oncovin

How was your experience with Oncovin?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking Oncovin?

What are you taking Oncovin for?

Choose one
  • Other
  • Hodgkin Disease
  • Leukemia
  • Lymphoma, Non-hodgkin
  • Neuroblastoma
  • Rhabdomyosarcoma

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did Oncovin work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend Oncovin to a friend?

Oncovin Cautionary Labels

precautionsprecautionsprecautionsprecautionsprecautions

Uses of Oncovin

Oncovin is a prescription medication used to treat acute leukemia. Oncovin is also used in combination with other medicines to treat Hodgkin’s disease, non-Hodgkin’s lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms’ tumor.

This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.

Oncovin Drug Class

Oncovin is part of the drug class:

Side Effects of Oncovin

Serious side effects have been reported with Oncovin. See the "Oncovin Precautions" section. 

Common side effects of Oncovin include the following:

  • hair loss
  • nausea
  • vomiting
  • diarrhea
  • a decrease in white blood cells and platelet counts
  • constipation
  • weakness, numbness, and pain, usually in the hands and feet (peripheral neuropathy)
  • stomach (abdominal) pain
  • weight loss
  • changes in taste and appetite
  • mouth sores
  • low amount of healthy blood cells in your blood (anemia)

This is not a complete list of Oncovin side effects. Ask your doctor or pharmacist for more information. 

Tell your doctor if you have any side effect that bothers you or that does not go away. 

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. 

Oncovin Interactions

Tell your doctor about all the medicines you take including prescription and non-prescription medicines, vitamins, and herbal supplements. Especially tell your doctor if you take:

  • medications that block a protein in the body (CYP3A4) such as some macrolide antibiotics (clarithromycin, telithromycin), some HIV protease inhibitors (indinavir, nelfinavir, ritonavir, saquinavir), some HCV protease inhibitors (boceprevir, telaprevir), some azole antifungals (ketoconazole, itraconazole, posaconazole, voriconazole), conivaptan (Vaprisol), delavirdine (Rescriptor), and nefazodone
  • vinca alkaloids such as vinblastine, vinorelbine, vincristine, and vindesine

This is not a complete list of Oncovin drug interactions. Ask your doctor or pharmacist for more information.

Oncovin Precautions

Serious side effects have been reported with Oncovin including the following:

  • kidney disease associated with high levels of uric acid (acute uric acid nephropathy)
  • nerves that control your voluntary muscles may be affected. Frequently, there is a sequence to the development of these side effects. First, only impairment of nerves involved with sensation and an abnormal sensation of tingling or pricking may occur. With continued treatment, pain from an inflamed nerve and, later, movement difficulties may occur. 
  • shortness of breath and severe constriction of airways (bronchospasm) have been reported. Progressive difficulty in breathing may require chronic therapy. Oncovin should not be readministered.
  • care must be taken to avoid getting Oncovin into the eye. If you get Oncovin in your eye then severe irritation (or, if the drug was delivered under pressure, even a cut on the eye) may result. Wash your eye out immediately and thoroughly.

This medication is for intravenous (IV) use only. Oncovin can cause death if given by other routes. 

Do not take Oncovin if you:

  • are allergic to Oncovin and any of its ingredients
  • have the demyelinating form of Charcot-Marie-Tooth syndrome

Oncovin Food Interactions

Medicines can interact with certain foods. In some cases, this may be harmful and your doctor may advise you to avoid certain foods. In the case of Oncovin there are no specific foods that you must exclude from your diet.

Inform MD

Before receiving this medication, tell your doctor about all of your medical conditions. Especially tell your doctor if:

  • you are allergic to any ingredient in Oncovin
  • you suffer from any diseases affecting the nerves or muscles
  • you are pregnant or breastfeeding

Tell your doctor about all the medicines you take including prescription and non-prescription medicines, vitamins, and herbal supplements.

Oncovin and Pregnancy

Tell your doctor if you are pregnant or plan to become pregnant.

The FDA categorizes medications based on safety for use during pregnancy. Five categories - A, B, C, D, and X, are used to classify the possible risks to an unborn baby when a medication is taken during pregnancy.

This medication falls into category D. Oncovin can cause birth defects for the baby if you are already pregnant. Both men and women should not plan on conceiving a child while on Oncovin. Your doctor can tell you when it will be safe to do so after treatment.

Oncovin and Lactation

Tell your doctor if you are breastfeeding or plan to breastfeed.

It is not known if Oncovin is excreted in human breast milk or if it will harm your nursing baby. Do not breastfeed while taking Oncovin.

Oncovin Usage

Oncovin is for intravenous (into the vein) use only. Your doctor will choose the correct dosage for your situation and in most cases will give the injection in his or her office or clinic.

Oncovin Dosage

Oncovin is for intravenous (into the vein) use only. Your doctor will choose the correct dosage for your situation and in most cases will give the injection in his or her office or clinic.

  • The usual dose for children is 1.5 to 2 mg/m2.
  • For children weighing 10 kg or less, the starting dose should be 0.05 mg/kg, administered once a week.
  • The usual dose for adults is 1.4 mg/m2.
  • A dose reduction may be necessary for patients with other medical conditions or receiving other medications.

Oncovin Overdose

Since this medication is administered by a healthcare provider in a medical setting, it is unlikely that an overdose will occur. However, if overdose is suspected, seek emergency medical attention.

Other Requirements

Keep all scheduled appointments with your doctor as well as all laboratory appointments. This medicine may cause a decrease of blood cells. Your doctor may order tests before, during and after your treatment to monitor this side effect.

Drink lots of water while receiving Oncovin treatments, unless you are told not to, to help prevent constipation and dehydration.

Good diet and nutrition will be helpful, as well as eating foods that will help reduce the effects of diarrhea.

People on Oncovin may be at risk of infections, so avoiding crowds or other people with contagious illnesses may help. Always maintain good hygiene and wash hands often.

Oncovin FDA Warning

WARNINGS

Caution–This preparation should be administered by individuals experienced in the administration of Oncovin It is extremely important that the intravenous needle or catheter be properly positioned before any Oncovin is injected. Leakage into surrounding tissue during intravenous administration of Oncovin may cause considerable irritation. If extravasation occurs, the injection should be discontinued immediately, and any remaining portion of the dose should then be introduced into another vein. Local injection of hyaluronidase and the application of moderate heat to the area of leakage help disperse the drug and are thought to minimize discomfort and the possibility of cellulitis.

FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES.